Indapta Therapeutics

Indapta Therapeutics, Inc. is a biotechnology company focused on developing and commercializing proprietary allogeneic cell therapies to treat various types of blood cancers and solid tumors. The company has developed allogeneic FcεRIγ-deficient natural killer cells, known as G-NK cells, and is working to bring this off-the-shelf cell therapy to patients to address the limitations of currently available autologous T-cell therapies.